Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Ellis

Sports Medicine Dublin, OH Medical Doctor

NPI 1124036645 CMS profile 964678

6810 Perimeter Dr Ste 200, Dublin, OH 43016

Open in the dashboard

General payments

$427,146

210 records reported · program years 2019–2025

Research payments

$20,000

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Ellis of Dublin, OH is reported in the CMS Open Payments database as having received $427,146 across 210 general payments and $20,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,142 19
2024 General $62,999 30
2023 General $65,028 23
2022 General $61,694 32
2021 General $58,700 17
2021 Research $10,000 1
2020 General $50,484 25
2020 Research $10,000 1
2019 General $99,098 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Ellis
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Thomas Ellis were reported at $29,142. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Thomas Ellis Sports Medicine median Middle half National median
2019 $99,098 $1,176 $199–$4,249 $163
2020 $50,484 $708 $96–$2,890 $114
2021 $58,700 $1,213 $152–$3,994 $132
2022 $61,694 $1,230 $159–$3,998 $149
2023 $65,028 $584 $146–$2,836 $160
2024 $62,999 $628 $163–$3,168 $164
2025 $29,142 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medacta USA, Inc. $421,118 167 payments
  2. Arthrex, Inc. $2,453 3 payments
  3. DePuy Synthes Products, Inc. $1,880 1 payment
  4. Graymont Professional Products IP, LLC $950 3 payments
  5. CDC Medical LLC $417 2 payments
  6. Horizon Therapeutics plc $184 29 payments
  7. Stryker Corporation $113 3 payments
  8. Djo, LLC $19 1 payment
  9. Pacira Pharmaceuticals Incorporated $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $360,070 37 payments
  2. Travel and Lodging $47,873 86 payments
  3. Honoraria $13,200 1 payment
  4. Food and Beverage $3,572 83 payments
  5. Education $2,431 3 payments
Products named General payments · program years 2019–2025
  1. AMISTEM $209,993 80 payments
  2. GMK SPHERE Knee $39,556 24 payments
  3. Mecta-C Cervical Cages $33,823 14 payments
  4. MyPAO Sport Medicine $23,706 2 payments
  5. MECTA Sports Medicine $21,556 10 payments
  6. GMK Sphere Orthopedics/Orthopedic Surgery $13,722 8 payments
  7. AMIStem H Femoral Stems $12,506 11 payments
  8. GMK Sphere Revision System $12,143 2 payments
  9. Mecta Orthopedics/Orthopedic Surgery $7,650 3 payments
  10. MyPAO Orthopedics/Orthopedic Surgery $5,076 5 payments
  11. Other $7,463 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medacta USA, Inc. $20,000 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

42

Median for Orthopedic Surgery: 203

Drug cost

$83

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cefadroxil Generic 12 $39
Famotidine Generic 12 $32
Amoxicillin Generic 18 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$18,089

Medicare's payments for the services billed

Medicare patients

43

Average age 64

Services billed

119

29 women, 14 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 42%
Heart failure 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record